Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Receives CE Mark for Molecular Test to Quantify Cytomegalovirus

NEW YORK ─ Marlborough, Massachusetts-based Hologic said on Wednesday that it has received the CE mark for its Aptima CMV Quant assay, making it available in Europe and other regions that accept the designation.

The assay quantifies the viral load of human cytomegalovirus to help diagnose and manage solid-organ transplant patients and hematopoietic stem cell transplant patients. It uses plasma and whole blood samples as well as real-time transcription-mediated amplification technology while running on Hologic's fully automated Panther system.

"Immunocompromised patients are vulnerable to a range of infections, with CMV [being] a frequent complication, and healthcare providers need to quantify and monitor CMV accurately," Jan Verstreken, group president, international, at Hologic, said in a statement.

The Aptima CMV Quant assay is the first in a new line of Hologic assays for transplant patients and demonstrates the firm's commitment to expand its molecular diagnostics business into new segments, Verstreken added.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.